Chapter 5: Renal Allograft Biopsy Wong Hin Seng

Slides:

Advertisements

Similar presentations

UK Renal Registry 16th Annual Report Figure Data completeness for key variables, stratified by first modality HD = haemodialysis; PD = peritoneal.

Advertisements

UK Renal Registry 17th Annual Report Figure Data completeness for key variables, stratified by first modality DOB = date of birth; PRD = primary.

The Value of Zero-Hour Implantation Biopsies Volker Nickeleit Nephropathology Laboratory, Department of Pathology The University of North Carolina, Chapel.

The value of protocol biopsies in renal allografts Gordana Petrusevska Skopje, Macedonia Gordana Petrusevska Skopje, Macedonia.

Slide 1PUBLICATIONS Racusen/Solez meeting report for AJT. Racusen/Solez meeting report for AJT. Manuscript on antibody-mediated rejection. Manuscript on.

Calcineurin Inhibitor Toxicity In Kidney Allograft Protocol Biopsies Neeraja Kambham M.D. Stanford University.

GRADING OF REJECTION IN PANCREAS ALLOGRAFTS Are changes needed? Cinthia B. Drachenberg, M.D. University of Maryland School of Medicine Baltimore MD.

Slide Seminar Drugs and Kidney Case 3 Heinz Regele Department of Pathology.

Sum Scores and Scores of Individual Components in Clinical Practice and Clinical Trials Lillian W. Gaber University of Tennessee.

Lupus Nephritis in Children Renal involvement in SLE: 30% - 70% Renal involvement in SLE: 30% - 70% Most diagnosis in adolescence, rare < 5y/o Most diagnosis.

Recurrent And De Novo GN After Renal Transplantation

Table 5.1.1: Stock and Flow of Renal Transplantation, Year New transplant patients

Pathology of Kidney and the Urinary tract

Study of cytokine gene polymorphism and graft outcome in live-donor kidney transplantation By Rashad Hassan MD Amgad El-Agroudy, Ahmad Hamdy, Amani Mostafa.

Interactive Case Discussion Case 6 Dr Megha S Uppin Asst Prof Dept of Pathology Nizam’s Institute of Medical Sciences Hyderabad.

CHAPTER 5: PAEDIATRIC RENAL REPLACEMENT THERAPY Lee Ming Lee Lim Yam Ngo Lynster Liaw Susan Pee Yap Yok Chin Wan Jazilah Wan Ismail Source: 21 st MDTR.

Pathology of Kidney and the Urinary tract Dr. Amar C. Al-Rikabi Dr. Hala Kasouf Kfouri.

CHAPTER 4 Paediatric Renal Biopsies Lee Ming Lee Lim Yam Ngo Lynster Liaw Mirunalini a/p Appadurai Selva Kumar a/l Sivapuniam Susan Pee Wan Jazilah Wan.

Table 5.1.1: Stock and Flow of Renal Transplantation, Year New transplant patients

Chapter 11 Paediatrics 2014 ANZDATA Registry 37th Annual Report Data to 31-Dec-2013 ANZDATA gratefully acknowledges the contributions of the Paediatric.

CHAPTER 1 Overview of Renal Biopsy in Malaysia Wan Sha’ariah Md Yusuf Lee Ming Lee Lee Day Guat.

UK National Renal Transplant EQA Scheme Ian Roberts Department of Cellular Pathology, Oxford Radcliffe Hospitals The National Renal Transplant EQA Scheme.

2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 7: Transplantation.

C4d in pancreas transplant biopsies: the Leiden experience Ingeborg Bajema Ingeborg Bajema Ingeborg Bajema.

Table 3.1.1: Stock and Flow of Heart Transplantation, Year New transplant patients Deaths

CHAPTER 13 Renal Transplantation Goh Bak Leong Fan Kin Sing Rohan Malek Bin Dato’ Dr. Johan Rosnawati Yahya S. Prasad Menon Tan Si Yen Wong Hin Seng Source:

U Chronic renal failure secondary to ? Hepatitis C.

TM RAPAMUNE ® O-1 RAPAMUNE ® Overview John F. Neylan, MD Vice President, Transplantation Immunology Clinical Research and Development Wyeth-Ayerst Research.

Table 3.1.1: Stock and Flow of Heart Transplantation, Year New transplant patients Deaths

CHAPTER 5 Renal Allograft Biopsy Wong Hin Seng 5 th MRRB report 2011 & 2012, Malaysia.

U # Chronic renal failure – secondary to IgA nephropathy. Deceased donor kidney transplant – August Complicated by delayed graft.

CHAPTER 2 DIALYSIS IN MALAYSIA Goh Bak Leong Lim Yam Ngo Ong Loke Meng Ghazali Ahmad Lee Day Guat Source: 20 th MDTR Report 2012, NRR.

Pathology of Renal Transplantation

Clinico-pathological Analysis of Kidney Diseases in Children: A Retrospective, Single Center Study Dr. Bassam Saeed Pediatric Nephrologist Surgical Kidney.

U # LRD kid tx March/99 Original Dis IgA.

CHAPTER 4: Paediatric Renal Biopsies

Smooth muscle–specific actin levels in the urine of renal transplant recipients: Correlation with cyclosporine or tacrolimus nephrotoxicity Mark Haas,

Table 1.2.1: Total number of renal biopsies by centres, 2005 – 2012

U # /121 Cad Tx 14/05/2004 Creatinine early December US normal.

Table 3.1.1a: Stock and Flow of Heart Transplantation,

Title: POST RENAL TRANSPLANT DIABETIC NEPHROPATHY By:Ayman Maher Nagib, Yasser Elsayed Matter, Mohamed Megahed Aboulmagd, Osama Ashry Gheith, Ayman.

KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients 순천향대학교 서울병원 신장내과 R2 김윤석.

Chapter 12 Liver Transplantation 1

Orthotopic liver transplant, recurrent non-alcoholic steatohepatitis

CHAPTER 5 Paediatric Renal Replacement Therapy

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2010

IgA Nephropathy Southwest Nephrology Symposium February 24th 2018.

CHAPTER 1 All Renal Replacement Therapy In Malaysia

Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetil Q. Sun, Z-H. Liu, Z. Cheng, J. Chen,

West Midlands Renal Peer Review

What is the long-term outcome of the liver allograft?

An Observational Study on Thrombotic Microangiopathy in Renal Transplant Recipients - A Tertiary Care Centre Experience. Dr Sarang Vijayan Senior Resident.

UK Renal Registry 16th Annual Report

αvβ6 integrin expression in diseased and transplanted kidneys

Volume 85, Issue 1, Pages (January 2014)

Prevention of renal failure: The Malaysian experience

Volume 69, Issue 10, Pages (May 2006)

Volume 76, Issue 5, Pages (September 2009)

Volume 67, Issue 1, Pages (January 2005)

Volume 64, Issue 3, Pages (September 2003)

CHAPTER 2 PRIMARY GLOMERULONEPHRITIS

Post-transplant membranous glomerulonephritis as a manifestation of chronic antibody-mediated rejection Hyeon Joo Jeong, Beom Jin Lim, Myoung Soo Kima,

Endothelin antagonists in renal disease

Inflammatory cells in ischemic acute renal failure

Volume 71, Issue 12, Pages (June 2007)

Worldwide incidence of ESRD figure 12.1, per million population

Volume 65, Issue 5, Pages (May 2004)

Volume 70, Issue 6, Pages (September 2006)

Relationship between time from diagnosis of type 2 diabetes to renal biopsy and the proportion of biopsies with any diabetic nephropathy (DN) and any non-diabetic.

Avasare et al. Am J Nephrol 2017;45:99-106 (DOI: / )

Presentation transcript:

Chapter 5: Renal Allograft Biopsy Wong Hin Seng

Table 5.2.1: Number of renal allograft biopsy, 2004-2010 Year 2004 2005 2006 2007 2008 2009 2010 Total Number of renal transplant biopsy 52 71 118 124 133 180 802 4th MRRB report 2010, Malaysia

Figure 5.2.1: Number of renal allograft biopsy, 2004-2010 20 40 60 80 100 120 140 160 180 200 2004 2005 2006 2007 2008 2009 2010 Year Number of renal transplant biopsy Allograft biospy 4th MRRB report 2010, Malaysia

Table 5.2.2: Number of renal allograft biopsy by centre, 2004-2010 4th MRRB report 2010, Malaysia

4th MRRB report 2010, Malaysia Table 5.2.3: Renal allograft biopsy by year and age group, rate per million population, 2004-2010 Age group 2004 2005 2006 2007 n % Rate <15 3 5.8 0.0 6 5.1 0.1 7 5.6 15-<25 14 26.9 0.3 15 21.1 25 21.2 0.5 19 15.3 0.4 25-<35 28.8 11 15.5 0.2 0.6 12.1 35-<45 23 32.4 26 22.0 0.7 49 39.5 1.2 45-<55 5 9.6 12 16.9 24 20.3 0.8 19.4 55-<65 1 1.9 8 11.3 6.8 10 8.1 >65 2 2.8 4 3.4 Total 52 100 71 118 124 4th MRRB report 2010, Malaysia

4th MRRB report 2010, Malaysia Continue; Age group 2008 2009 2010 Total n % Rate <15 9 7.3 0.1 6.8 8 4.4 42 5.2 15-<25 22 17.7 0.4 17 12.8 0.3 21 11.7 133 16.6 25-<35 20 16.1 30 22.6 0.6 29 145 18.1 0.5 35-<45 25 20.2 24 18 66 36.7 1.6 227 28.3 0.8 45-<55 35 28.2 1.1 36 27.1 40 22.2 1.2 176 21.9 0.9 55-<65 16 12 6.7 64 >65 4 3.2 1 2.2 15 1.9 0.2 124 100 180 802 4th MRRB report 2010, Malaysia

4th MRRB report 2010, Malaysia Figure 5.2.3: Renal allograft biopsy by year and age group, rate per million population, 2004-2010 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2004 2005 2006 2007 2008 2009 2010 Year Rate (Per million population) <15 15-<25 25-<35 35-<45 45-<55 55-<65 >65 4th MRRB report 2010, Malaysia

Table 5.3: Indications for renal allograft biopsy, 2004-2010 * Patients may have one or more clinical presentation * 48 patients have no information on clinical presentation (neither urine abnormalities nor graft function) For 2004, 1 patient has 2 indications For 2006, 4 patients have 2 indications For 2007, 5 patients have 2 indications For 2008, 6 patients have 2 indications For 2009, 11 patients have 2 indications For 2010, 7 patients have 2 indications 4th MRRB report 2010, Malaysia

>1 yr post transplant 4th MRRB report 2010, Malaysia Table 5.4: Timing of renal allograft biopsy, 2004-2010 (dates: date of biopsy & date of transplant) Timing of renal transplant biopsy Within 1 week >1 week to 1month > 1month to 3 months > 3 months to 6 months > 6months to 1 year >1 yr post transplant Total n % 2004 2 3.8 9 17.3 12 23.1 8 15.4 3 5.8 18 34.6 52 100 2005 1 1.4 12.7 11.3 16.9 6 8.5 35 49.3 71 2006 4 3.4 15 13 11.0 7.6 68 57.6 118 2007 5 4.0 14 12.1 10 8.1 6.5 72 58.1 124 2008 4.8 10.5 17 13.7 11 8.9 69 55.6 2009 20 15.0 6.0 4.5 79 59.4 133 2010 3.3 40 22.2 28 15.6 21 11.7 7.2 40.0 180 29 3.6 115 14.3 113 14.1 76 9.5 56 7.0 413 51.5 802 4th MRRB report 2010, Malaysia

Figure 5.4: Timing of renal allograft biopsy, 2004-2010 10 20 30 40 50 60 70 80 90 2004 2005 2006 2007 2008 2009 2010 Year NUmber of timing of graft biopsy Within 1 week >1 week to 1month > 1month to 3 months > 3 months to 6 months > 6months to 1 year >1 yr post transplant 4th MRRB report 2010, Malaysia

4th MRRB report 2010, Malaysia Table 5.5.1: Biopsy method, 2004-2011 *No data on biopsy technique 4th MRRB report 2010, Malaysia

Figure 5.5.1: Biopsy method (censored for missing data), 2004-2010 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 2004 2005 2006 2007 2008 2009 2010 Year Propotion of biopsy method Blind Not US guided US guided: Real time US guided: Not real-time 4th MRRB report 2010, Malaysia

Table 5.5.2: Number of passes, 2004-2011 4th MRRB report 2010, Malaysia

Figure 5.5.2: Number of passes, 2004-2011 10 20 30 40 50 60 70 2004 2005 2006 2007 2008 2009 2010 Year Percentage (%) 1 2 3 4 5 6 4th MRRB report 2010, Malaysia

Table 5.5.3: Number of glomeruli obtained on biopsy, 2004-2010 * No data information on the number of glomeruli 4th MRRB report 2010, Malaysia

Figure 5.5.3: Number of glomeruli obtained on biopsy, 2004-2010 10 20 30 40 50 60 2004 2005 2006 2007 2008 2009 2010 Year Percentage (%) 1-9 10-19 >20 Missing/Unknown* 4th MRRB report 2010, Malaysia

Table 5.5.4: Type of complications, 2004-2011 a Mild complication is defined as presence of gross hematuria, perirenal collection, hematoma, or AVM that do not require intervention b Severe complication is defined as presence of hypotension or complications requiring intervention. c No data information for complications 4th MRRB report 2010, Malaysia

Figure 5.6: Histological diagnosis, 2004-2010 10 20 30 40 50 60 2004 2005 2006 2007 2008 2009 2010 Year Percentage(%) Acute rejection Borderline rejection Calcineurin inhibitor toxicity Chronic allograft nephropathy Acute tubular necrosis PTLD** De novo Recurrent GN Diabetic nephropathy Others 4th MRRB report 2010, Malaysia

Table 5.6 Histological diagnosis, 2004-2010 * Patients may have more than 1 diagnosis classification **Post Transplant Lymphoproliferative disease 4th MRRB report 2010, Malaysia